Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy

Kidney and Blood Pressure Research

Volumn 32, Issue 1, 2009, Pages 24-31

  Diamanti Kandarakis, Evanthia ^a,b   Economou, Frangiskos N ^a   Livadas, Sarantis ^a   Tantalaki, Evangelia ^a   Piperi, Christina ^b   Papavassiliou, Athanasios G ^b   Panidis, Dimitrios ^c  

^a Endocrine Section

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Aldosterone; Metformin; Polycystic ovary syndrome; Prorenin; Renin

Indexed keywords

ALDOSTERONE; ANDROGEN; GLUCOSE; INSULIN; METFORMIN; RENIN; TESTOSTERONE;

ABSENCE OF SIDE EFFECTS; ADULT; ANOVULATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; FEMALE; HUMAN; HYPERANDROGENISM; HYPERRENINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL;

ADULT; ALDOSTERONE; ANDROGENS; AREA UNDER CURVE; BLOOD GLUCOSE; CASE-CONTROL STUDIES; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; METFORMIN; POLYCYSTIC OVARY SYNDROME; RENIN; TREATMENT OUTCOME;

EID: 59749085606     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000201791     Document Type: Article

References (64)

1. Ehrmann DA: Polycystic ovary syndrome. N Engl J Med 2005;352:1223-1236.
2. Diamanti-Kandarakis E: Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med 2008;10:e3.
3. Diamanti-Kandarakis E, Economou F: Stress in women: metabolic syndrome and polycystic ovary syndrome. Ann NY Acad Sci 2006;1083:54-62.
4. Dunaif A, Segal KR, Futterweit W, Dobrjansky A: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
5. Cussons AJ, Stuckey BG, Watts GF: Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006;185:227-239.
6. Shaw LJ, Bairey Merz CN, Azziz R, et al: Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health - National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008;93:1276-1284.
7. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M: Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985;312:1412-1417.
8. Wilson DM, Luetscher JA: Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. N Engl J Med 1990;323:1101-1106.
9. Nguyen G, Bouzhir L, Delarue F, Rondeau E, Sraer JD: Evidence of a renin receptor on human mesangial cells: effects on PAI1 and cGMP (in French). Nephrologie 1998;19:411-416.
10. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD: Pivotal role of the renin/ prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-1427.
11. Batenburg WW, Krop M, Garrelds IM, et al: Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens 2007;25:2441-2453.
12. Nabi AH, Kageshima A, Uddin MN, Nakagawa T, Park EY, Suzuki F: Binding properties of rat prorenin and renin to the recombinant rat renin/prorenin receptor prepared by a baculovirus expression system. Int J Mol Med 2006;18:483-488.
13. Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD: Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996;50:1897-1903.
14. Feldt S, Batenburg WW, Mazak I, et al: Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008;51:682-688.
15. Huang Y, Wongamorntham S, Kasting J, et al: Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006;69:105-113.
16. Huang Y, Noble NA, Zhang J, Xu C, Border WA: Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 2007;72:45-52.
17. Allen TJ, Cooper ME, Gilbert RE, Winikoff J, Skinni SL, Jerums G: Serum total renin is increased before microalbuminuria in diabetes. Kidney Int 1996;50:902-907.
18. Makimattila S, Summanen P, Matinlauri I, et al: Serum total renin, an independent marker of the activity and severity of retinopathy in patients with IDDM. Br J Ophthalmol 1998;82:939-944.
19. Glorioso N, Atlas SA, Laragh JH, Jewelewicz R, Sealey JE: Prorenin in high concentrations in human ovarian follicular fluid. Science 1986;233:1422-1424.
20. Itskovitz J, Rubattu S, Rosenwaks Z, Liu HC, Sealey JE: Relationship of follicular fluid prorenin to oocyte maturation, steroid levels, and outcome of in vitro fertilization. J Clin Endocrinol Metab 1991;72:165-171.
21. Palumbo A, Pourmotabbed G, Carcangiu ML, et al: Immunohistochemical localization of renin and angiotensin in the ovary: comparison between normal women and patients with histologically proven polycystic ovarian disease. Fertil Steril 1993;60:280-284.
22. Zawadski JK, Dunaif A: Diagnostic Criteria for Polycystic Ovary Syndrome: towards a Rational Approach. Polycystic Ovary Syndrome. Boston, Blackwell Scientific, 1992, pp 377-384.
23. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
24. Katz A, Nambi SS, Mather K, et al: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410.
25. Bergman RN, Prager R, Volund A, Olefsky JM: Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987;79:790-800.
26. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470.
27. Tai MM: A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 1994;17:152-154.
28. Deinum J, Derkx FH, Schalekamp MA: Improved immunoradiometric assay for plasma renin. Clin Chem 1999;45:847-854.
29. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, Katsilambros N, Kreatsas G, Panidis D: Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006;21:1426-1431.
30. Derkx FH, de Bruin RJ, van Gool JM, et al: Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity. Clin Chem 1996;42:1051-1063.
31. Jaatinen TA, Matinlauri I, Anttila L, Koskinen P, Erkkola R, Irjala K: Serum total renin is elevated in women with polycystic ovarian syndrome. Fertil Steril 1995;63:1000-1004.
32. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP: Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997;100:2158-2169.
33. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR: Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 1996;93:12490-12495.
34. Danser AH, van Kesteren CA, Bax WA, et al: Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation 1997;96:220-226.
35. Singh HJ, Rahman A, Larmie ET, Nila A: Raised prorenin and renin concentrations in pre-eclamptic placentae when measured after acid activation. Placenta 2004;25:631-636.
36. Chiarelli F, Pomilio M, De Luca FA, Vecchiet J, Verrotti A: Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Pediatr Nephrol 2001;16:116-120.
37. Daneman D, Crompton CH, Balfe JW, et al: Plasma prorenin as an early marker of nephropathy in diabetic (IDDM) adolescents. Kidney Int 1994;46:1154-1159.
38. Deinum J, Tarnow L, van Gool JM, et al: Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy. Nephrol Dial Transplant 1999;14:1904-1911.
39. Deinum J, Ronn B, Mathiesen E, Derkx FH, Hop WC, Schalekamp MA: Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999;42:1006-1010.
40. Danser AH, van den Dorpel MA, Deinum J, et al: Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989;68:160-167.
41. Wilson DM, Luetscher JA: Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. N Engl J Med 1990;323:1101-1106.
42. Yokota H, Mori F, Kai K, et al: Serum prorenin levels and diabetic retinopathy in type 2 diabetes: new method to measure serum level of prorenin using antibody activating direct kinetic assay. Br J Ophthalmol 2005;89:871-873.
43. Diamanti-Kandarakis E, Paterakis T, Kandarakis HA: Indices of low-grade inflammation in polycystic ovary syndrome. Ann NY Acad Sci 2006;1092:175-186.
44. Diamanti-Kandarakis E, Alexandraki K, Piperi C, et al: Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 2006;36:691-697.
45. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N: Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:2453-2455.
46. Ikeda T, Ochi H: Glucose stimulates renin secretion via adrenergic mechanisms in the rat. Life Sci 1998;62:1999-2004.
47. Sverrisdottir YB, Mogren T, Kataoka J, Janson PO, Stener-Victorin E: Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? Am J Physiol Endocrinol Metab 2008;294:E576-E581.
48. Do YS, Sherrod A, Lobo RA, et al: Human ovarian theca cells are a source of renin. Proc Natl Acad Sci USA 1988;85:1957-1961.
49. Anderson PW, Macaulay L, Do YS, et al: Extrarenal renin-secreting tumors: insights into hypertension and ovarian renin production. Medicine (Baltimore) 1989;68:257-268.
50. Anderson PW, d'Ablaing G 3rd, Penny R, Sherrod A, Do YS: Secretion of prorenin by a virilizing ovarian tumor. Gynecol Oncol 1992;45:58-61.
51. Chen YF, Naftilan AJ, Oparil S: Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension 1992;19:456-463.
52. Reckelhoff JF: Gender differences in the regulation of blood pressure. Hypertension 2001;37:1199-1208.
53. Sealey JE, Atlas SA, Laragh JH: Prorenin and other large molecular weight forms of renin. Endocr Rev 1980;1:365-391.
54. King AJ, Olivier NB, Mohankumar PS, Lee JS, Padmanabhan V, Fink GD: Hypertension caused by prenatal testosterone excess in female sheep. Am J Physiol Endocrinol Metab 2007;292:E1837-E1841.
55. Cascella T, Palomba S, Tauchmanova L, et al: Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2006;91:4395-4400.
56. Szmuilowicz ED, Adler GK, Williams JS, Green DE, Yao TM, Hopkins PN, Seely EW: Relationship between aldosterone and progesterone in the human menstrual cycle. J Clin Endocrinol Metab 2006;91:3981-3987.
57. Chidambaram M, Duncan JA, Lai VS, Cattran DC, Floras JS, Scholey JW, Miller JA: Variation in the renin angiotensin system throughout the normal menstrual cycle. J Am Soc Nephrol 2002;13:446-452.
58. Morris RS, Wong IL, Hatch IE, Gentschein E, Paulson RJ, Lobo RA: Prorenin is elevated in polycystic ovary syndrome and may reflect hyperandrogenism. Fertil Steril 1995;64:1099-1103.
59. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998;138:269-274.
60. Lord JM, Flight IH, Norman RJ: Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327:951-953.
61. Nestler JE, Jakubowicz DJ: Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617-623.
62. Rossi G, Boscaro M, Ronconi V, Funder JW: Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005;16:104-107.
63. Struthers AD: Aldosterone in heart failure: pathophysiology and treatment. Curr Heart Fail Rep 2004;1:171-175.
64. Orio F Jr, Giallauria F, Palomba S, Cascella T, Manguso F, Vuolo L, Russo T, Tolino A, Lombardi G, Colao A, Vigorito C: Cardiopulmonary impairment in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:2967-2971.